Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of the ablative effect of intravesical Immucothel in superficial papillary bladder cancer with a marker lesion
2005-003809-86Phase 2Completed
- Sponsor
- Arbeitskreis für urologische Onkologie
- Start
- May 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IMG KLH in transitional cell carcinoma of the bladder (TCC), non-muscle-invasive bladder cancer (NMIBC), sponsored by Arbeitskreis für urologische Onkologie. Started May 2007; status: completed.
02
Drugs
IMG KLH
03
Conditions
transitional cell carcinoma of the bladder (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2005-003809-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003809-86.